How Can Hepatitis C Be Contracted?

At one time, before 1990, the most common way that Hepatitis C was spread to others was believed to be by tainted blood used in transfusions. But then the medical community found a way to test blood for the HCV infection and this risk as all but been eliminated as a cause of this very infectious disease. Before this testing began the risk of contracting Hepatitis C from tainted blood was one in two hundred.  The first tests, which began in 1990, were not great, giving off many false positives.  Within two years new improved tests, more sensitive to what was being looked for lowered the odds of getting infected blood to one in one hundred thousand.

Unfortunately there are many other ways that Hepatitis C can be passed from one infected person to another. Those in the community who are drug users are probably among the highest risk group. The sharing of any appliance or equipment used in taking drugs is one of the easiest methods of transferring this disease. That includes sharing needles or any other piece of equipment that may have blood or body fluids on it.   

Receiving an organ for transplant from someone who had the Hepatitis C virus, HCV, can give the recipient hepatitis.  Someone who is a hemophiliac or has chronic kidney failure is in the high-risk category because they are constantly exposed to blood products to keep them alive.  Health care workers must be very cautious when doing their jobs because they are in a potentially high-risk profession. A simple mistake, like pricking their finger with a needle that has blood on it from someone with the hepatitis C virus, can infect them.

For all those people who want to express themselves by getting a tattoo or a piercing you could also be at risk. Make sure that the place you go follows some basic hygiene practices. Those must include using only sterile needles when doing their job. Don't allow them to take a needle out of a drawer and begin unless the needle is in an unopened package and so will be used only for you. Otherwise, truthfully, you have no idea what diseases you could be at risk for. The tiniest bit of blood on a used needle could be all that is needed to change your life by giving you hepatitis, or even something worse. If they don't use sterile needles find somewhere that does.

Other potential risks come from sharing anything that could have blood on it. This includes a toothbrush or a razor belonging to an infected person. 

If your partner has HCV and you both remain as a monogamous couple your chance of contracting it are low, at about five percent. But if someone has multiple sexual partners, and does not practice safe sex by using condoms, they slip into the high-risk category. The unnerving part of this disease is that in about ten percent of all cases there is no obvious means of having caught the infection.

Hepatitis news on the Web

As death nears, hepatitis C victim to give videotaped deposition in Desai case - Las Vegas Review-Journal

As death nears, hepatitis C victim to give videotaped deposition in Desai case
Las Vegas Review-Journal
Rodolfo Meana, pictured here in 2008, is one of seven patients diagnosed with hepatitis C that has been genetically linked to the Endoscopy Center of Southern Nevada. Meana's doctors have told him he is terminally ill. » Buy this photo Dr. Dipak Desai ...

and more »

BioLineRx Licenses Another Hepatitis C Drug From Genoscience - Wall Street Journal

BioLineRx Licenses Another Hepatitis C Drug From Genoscience
Wall Street Journal
BioLineRx Ltd. (BLRX) licensed another Hepatitis C treatment from French biotechnology company Genoscience, as the Israeli-based biopharmaceutical company expands into the field of Hepatitis C therapeutics. Hepatitis C is a blood-borne infection of the ...
BioLineRx In-Licenses Second Oral Hepatitis C TreatmentMarketWatch (press release)
BiolineRX signs second hepatitis C licensing dealGlobes

all 24 news articles »

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ... - FierceBiotech

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ...
FierceBiotech
Article | Follow @FierceBiotech @JohnCFierce: So does BioLineRx see itself as a hep C co. now that it has in-licensed a 2nd program, or is this about share price? Release | Follow @JohnCFierce @FierceMedDev: DNA-sequencing penetrates Norway's ...

and more »

Gilead Sciences Jumps on Hepatitis C Data - Pharmaceutical Processing

Gilead Sciences Jumps on Hepatitis C Data
Pharmaceutical Processing
NEW YORK (AP) — Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing. THE SPARK: Gilead said Thursday that in a clinical trial, ...
Does Anavex Life Sciences (AVXL) Have the Next Big Thing Big Pharma Wants?SmallCap Network
Positive Clinical Trial Results Boost Gilead the Most in Three Years – NASDAQ:GILDGalaxy Stocks
Gilead stock rises on potential hepatitis C cureSan Francisco Business Times (blog)
Proactive Investors USA & Canada -Seeking Alpha -CNBC.com
all 12 news articles »

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
An all-oral hepatitis C drug may be one step closer to realityLagonian.com
Gilead Up 6% After Positive Hep-C TrialWall St. Cheat Sheet
DailyFinance -24/7 Wall St.
all 63 news articles »

Culture: Impact of war on language (155) - Egyptian Gazette

Culture: Impact of war on language (155)
Egyptian Gazette
In several studies of Veteran's Affairs (VA) Medical Centre patients, we find that 8-9% are positive for hepatitis C antibodies. Some VA Medical Centres had 10-20% of patients with hepatitis C antibodies. According to Dr Bradford Waters, Professor of ...

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
Idenix Says FDA Lifts Partial Hold On Hepatitis Drug IDX184; But Stock DownNASDAQ
PR Newswire (press release)
all 31 news articles »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex Falls as Analyst Cuts Sales Estimates on Hepatitis C PillBloomberg
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
LocalizedUSA -Financial News Network Online
all 15 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge

all 5 news articles »

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ... - Gastroenterology & Endoscopy News

Gastroenterology & Endoscopy News

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ...
Gastroenterology & Endoscopy News
by Christina Frangou A combination therapy including two investigational direct-acting antiviral agents (DAAs)—asunaprevir and daclatasvir—suppressed hepatitis C virus (HCV) genotype 1 infection in a majority of patients who had previously not ...


Google News